ArticleMikrochimica acta2024
Dendritic mesoporous silica loaded with gold nanoclusters and their application in immunochromatographic assay.
Article in Mikrochimica acta, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Novel green-emitting fluorescent microspheres (GreFMPs) were assembled by loading highly luminescent gold nanoclusters (Arg/ATT/AuNCs) on dendritic mesoporous silica nanoparticles (DMSNs) via PEI-mediated electrostatic adsorption. The fluorescence microspheres exhibit excellent monodispersion with average diameters about (254.5 ± 34.6 nm). Compared with free Arg/ATT/AuNCs, the GreFMPs have similar fluorescent properties and biocompatibility but superior environmental tolerance. Subsequently, an immunochromatographic assay based on GreFMPs (GreFMP-ICA) has been successfully developed, which is highly selective toward alpha fetoprotein (AFP) in human serum. Under the optimal parameters, there is a good linear range between 0.5 and 160.0 ng/mL, the limit of detection was found to be about 0.5 ng/mL, and the recovery and relative standard deviation are 81.0 ~ 100.6% and 3.5 ~ 16.6%, respectively. These results manifested that the GreFMPs are beneficial for the rational design of the ICA platform, and the proposed GreFMP-ICA has the potential to screen AFP in clinical applications.
Indexed as
Identifiers
39499405What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.